VIA
LGND icon

Virtus Investment Advisers’s Ligand Pharmaceuticals LGND Stock Holding History

Virtus Investment Advisers’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.44M Buy
4,551
+98
+2% +$23.1K 0.34% 128
2026
Q1 		$889K Buy
4,453
+848
+24% +$168K 0.25% 152
2025
Q4 		$682K Sell
3,605
-278
-7% -$53.4K 0.19% 184
2025
Q3 		$688K Hold
3,883
– – 0.2% 171
2025
Q2 		$441K Buy
3,883
+721
+23% +$77.1K 0.15% 203
2025
Q1 		$332K Buy
+3,162
New +$358K 0.09% 234

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtus Investment Advisers's LGND Position: Q2 2026 in Review

Virtus Investment Advisers increased its Ligand Pharmaceuticals (LGND) stake by 2.2% in Q2 2026, buying an estimated $23.1K and bringing the position to 4,551 shares worth $1.44M. The position accounts for 0.34% of the portfolio, ranked #128.

Virtus Investment Advisers first reported a position in LGND in Q1 2025 and has held it in 6 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Virtus Investment Advisers held 4,551 shares of Ligand Pharmaceuticals worth $1.44M as of Q2 2026.
  • Virtus Investment Advisers bought 98 Ligand Pharmaceuticals shares in Q2 2026, an estimated $23.1K.
  • Ligand Pharmaceuticals made up 0.34% of Virtus Investment Advisers's portfolio in Q2 2026, its #128 holding.
  • Virtus Investment Advisers first reported a position in Ligand Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.